Yadav AK, Shukla R, Flora S. Nanomedical Drug Supply for neurodegenerative Illnesses. Educational Press; 2022.
Cano A, et al. Present advances within the improvement of novel polymeric nanoparticles for the therapy of neurodegenerative illnesses. Nanomedicine. 2020;15(12):1239–61.
Singh AK, et al. Position of TREM2 in Alzheimer’s Illness and its penalties on β-amyloid, tau and neurofibrillary tangles. Curr Alzheimer Res. 2019;16(13):1216–29.
Jagaran Okay, Singh M. Nanomedicine for neurodegenerative problems: Concentrate on Alzheimer’s and Parkinson’s illnesses. Int J Mol Sci. 2021;22(16):9082.
Veeman D, et al. Systematic assessment on 9 hallmarks of neurodegenerative Illness. Indian J Biochem Biophys (IJBB). 2022;59(3):249–57.
Checkoway H, Lundin JI, Kelada SN. Neurodegenerative illnesses. IARC Sci Publ, 2011(163): p. 407–19.
Sweeney P, et al. Protein misfolding in neurodegenerative Illnesses: implications and methods. Translational Neurodegeneration. 2017;6(1):1–13.
Madabhushi R, Pan L, Tsai L-H. DNA injury and its hyperlinks to neurodegeneration. Neuron. 2014;83(2):266–82.
Bhat AH, et al. Oxidative stress, mitochondrial dysfunction and neurodegenerative illnesses; a mechanistic perception. Biomed Pharmacother. 2015;74:101–10.
Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative illnesses. Nature. 2006;443(7113):787–95.
Patterson C. The cutting-edge of dementia analysis: New frontiers World Alzheimer Report, 2018. 2018.
Goel P, et al. Neuronal cell loss of life mechanisms in Alzheimer’s Illness: an perception. Entrance Mol Neurosci. 2022;15:937133.
Taliyan R et al. Nanocarrier mediated drug supply as an impeccable therapeutic strategy in opposition to Alzheimer’s Illness. J Managed Launch, 2022.
Swetha G et al. Convolutional Neural Networks Mannequin for Parkinson Illness Detection from Photographs and Voice Information
Floel A, et al. Levodopa will increase reminiscence encoding and dopamine launch within the striatum within the aged. Neurobiol Ageing. 2008;29(2):267–79.
Connolly BS, Lang AE. Pharmacological therapy of Parkinson Illness: a assessment. JAMA. 2014;311(16):1670–83.
Eje O, et al. Huntington Illness: mechanism of Pathogenesis and up to date developments in its therapeutic methods: a assessment. J Chem Rev. 2023;5(2):129–42.
Bates GP, et al. Huntington Illness. Nat Critiques Illness Primers. 2015;1(1):1–21.
Carlesi C, et al. Methods for medical strategy to neurodegeneration in Amyotrophic Lateral Sclerosis. Arch Ital Biol. 2011;149(1):151–67.
Liu B, Hong J-S. Position of microglia in inflammation-mediated neurodegenerative illnesses: mechanisms and methods for therapeutic intervention. J Pharmacol Exp Ther. 2003;304(1):1–7.
Kabanov A, Gendelman HE. Nanomedicine within the prognosis and remedy of neurodegenerative problems. Prog Polym Sci. 2007;32(8–9):1054–82.
Shafique U, et al. High quality by design for sumatriptan loaded nano-ethosomal mucoadhesive gel for the therapeutic administration of nitroglycerin induced migraine. Int J Pharm. 2023;646:123480.
Raja HN, et al. Sodium alginate-based sensible gastro-retentive drug supply system of revaprazan loaded SLNs; Formulation and characterization. Int J Biol Macromol. 2023;253:127402.
Nguyen TT, et al. Nanotechnology-based drug supply for central nervous system problems. Quantity 143. Biomedicine & Pharmacotherapy; 2021. p. 112117.
Liu R, et al. Advances of nanoparticles as drug supply programs for Illness prognosis and therapy. Chin Chem Lett. 2023;34(2):107518.
Wilczewska AZ, et al. Nanoparticles as drug supply programs. Pharmacol Rep. 2012;64(5):1020–37.
Mir M, et al. Nanotechnology: from in vivo imaging system to managed drug supply. Nanoscale Res Lett. 2017;12:1–16.
Mulvihill JJ, et al. Drug supply throughout the blood–mind barrier: latest advances in the usage of nanocarriers. Nanomedicine. 2020;15(2):205–14.
Khan AS, et al. Improvement, in vitro and in vivo analysis of miltefosine loaded nanostructured lipid carriers for the therapy of cutaneous Leishmaniasis. Int J Pharm. 2021;593:120109.
Mukherjee S, et al. Current developments of nanomedicine in neurodegenerative problems theranostics. Adv Funct Mater. 2020;30(35):2003054.
Thomas T, Tajmir-Riahi H-A, Pillai C. Biodegradable polymers for gene supply. Molecules. 2019;24(20):3744.
Jamshaid H, Din FU, Khan GM. Nanotechnology primarily based options for anti-leishmanial impediments: an in depth perception. J Nanobiotechnol. 2021;19:1–51.
Batool S, et al. An in depth perception of the Tumor concentrating on utilizing nanocarrier drug supply system. Drug Supply. 2023;30(1):2183815.
Taylor JP, Hardy J, Fischbeck KH. Poisonous proteins in neurodegenerative Illness. Science. 2002;296(5575):1991–5.
Buckner RL, et al. Molecular, structural, and useful characterization of Alzheimer’s Illness: proof for a relationship between default exercise, amyloid, and reminiscence. J Neurosci. 2005;25(34):7709–17.
Bolognesi M, et al. MTDL design technique within the context of Alzheimer’s Illness: from lipocrine to memoquin and past. Curr Pharm Design. 2009;15(6):601–13.
Schneider LS, et al. Effectiveness of atypical antipsychotic Medication in sufferers with Alzheimer’s Illness. N Engl J Med. 2006;355(15):1525–38.
Lim GP, et al. The curry spice curcumin reduces oxidative injury and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001;21(21):8370–7.
Tobinick EL, Gross H. Speedy cognitive enchancment in Alzheimer’s Illness following perispinal etanercept administration. J Neuroinflamm. 2008;5(1):1–10.
Hunter KU, Yarbrough C, Ciacci J. Gene-and cell-based approaches for neurodegenerative Illness. Entrance Mind Restore, 2010: p. 117–30.
Tuszynski MH, et al. A section 1 medical trial of nerve progress issue gene remedy for Alzheimer Illness. Nat Med. 2005;11(5):551–5.
Opar A. Combined outcomes for disease-modification methods for Alzheimer’s Illness: high-profile programmes aiming to develop the primary disease-modifying drug for Alzheimer’s Illness have suffered main setbacks lately, however there’s nonetheless robust assist for a spread of efforts to remodel Illness therapy. Nat Rev Drug Discovery. 2008;7(9):717–9.
Alavijeh MS, et al. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx. 2005;2(4):554–71.
Weintraub D, Comella CL, Horn S. Parkinson’s Illness–half 1: pathophysiology, signs, burden, prognosis, and evaluation. Am J Manag Care. 2008;14(2 Suppl):S40–8.
Kordower JH, et al. Neurodegeneration prevented by lentiviral vector supply of GDNF in primate fashions of Parkinson’s Illness. Science. 2000;290(5492):767–73.
Manfredsson F, Lewin A, Mandel R. RNA knockdown as a possible therapeutic technique in Parkinson’s Illness. Gene Ther. 2006;13(6):517–24.
Khatoon M, et al. Improvement and analysis of optimized thiolated chitosan proniosomal gel containing duloxetine for intranasal supply. AAPS PharmSciTech. 2019;20:1–12.
Walker FO. Huntington’s Illness. The Lancet. 2007;369(9557):218–28.
Imarisio S, et al. Huntington’s Illness: from pathology and genetics to potential therapies. Biochem J. 2008;412(2):191–209.
Adam OR, Jankovic J. Symptomatic therapy of Huntington Illness. Neurotherapeutics. 2008;5(2):181–97.
Machida Y, et al. rAAV-mediated shRNA ameliorated neuropathology in Huntington Illness mannequin mouse. Biochem Biophys Res Commun. 2006;343(1):190–7.
Servais L, Van Damme P. Emergencies in Motor Neuron illnesses, in emergencies in Neuromuscular problems. Springer; 2022. pp. 155–80.
Sreedharan J, et al. TDP-43 mutations in familial and sporadic Amyotrophic Lateral Sclerosis. Science. 2008;319(5870):1668–72.
Vance C, et al. Mutations in FUS, an RNA processing protein, trigger familial Amyotrophic Lateral Sclerosis kind 6. Science. 2009;323(5918):1208–11.
DeJesus-Hernandez M et al. Expanded GGGGCC hexanucleotide repeat in noncoding area of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron, 2011. 72(2): p. 245–56.
Renton AE, et al. A hexanucleotide repeat enlargement in C9ORF72 is the reason for chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257–68.
Chua JP, et al. Autophagy and ALS: mechanistic insights and therapeutic implications. Autophagy. 2022;18(2):254–82.
Pardridge WM. The blood-brain barrier: bottleneck in mind drug improvement. NeuroRx. 2005;2(1):3–14.
Gad S, et al. Lipid nanocarriers encapsulating natural Medication for mind illnesses remedy. Archives of Pharmaceutical Sciences Ain Shams College. 2023;7(1):60–86.
Ehrlich P. Das sauerstoff-bedurfnis des organismus. Eine farbenanalytische studie, 1885.
Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in well being and Illness. Pharmacol Rev. 2005;57(2):173–85.
Reese T, Karnovsky MJ. Tremendous structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol. 1967;34(1):207–17.
Abbott NJ, Rönnbäck L, Hansson E. Astrocyte–endothelial interactions on the blood–mind barrier. Nat Rev Neurosci. 2006;7(1):41–53.
Raghav M et al. Nostril-to-brain drug supply: challenges and progress in direction of mind concentrating on within the therapy of neurological problems. J Drug Deliv Sci Technol, 2023: p. 104756.
Zlokovic BV. The blood-brain barrier in well being and continual neurodegenerative problems. Neuron. 2008;57(2):178–201.
Ghersi-Egea J-F, Minn A, Siest G. A brand new facet of the protecting capabilities of the blood-brain barrier: actions of 4 drug-metabolizing enzymes in remoted rat mind microvessels. Life Sci. 1988;42(24):2515–23.
Minn A, et al. Drug metabolizing enzymes within the mind and cerebral microvessels. Mind Res Rev. 1991;16(1):65–82.
Pardridge WM. Drug and gene supply to the mind: the vascular route. Neuron. 2002;36(4):555–8.
MacAulay N, Preserve RF, Zeuthen T. Cerebrospinal fluid manufacturing by the choroid plexus: a century of barrier analysis revisited. Fluids and Limitations of the CNS. 2022;19(1):1–18.
Pardridge WM. Current developments in peptide drug supply to the mind. Pharmacol Toxicol. 1992;71(1):3–10.
Wu D, et al. The blood–mind barrier: construction, regulation, and drug supply. Sign Transduct Goal Remedy. 2023;8(1):217.
Ekrami M et al. Nanotechnology-based Formulation for Various Medicines and Pure Merchandise: An Introduction with Scientific Research Biopolymers in Nutraceuticals and Practical Meals, 2022: p. 545 – 80.
Re F, Gregori M, Masserini M. Nanotechnology for neurodegenerative problems. Maturitas. 2012;73(1):45–51.
Choi H, et al. Methods for focused supply of exosomes to the mind: benefits and challenges. Pharmaceutics. 2022;14(3):672.
Wei X, et al. Mind tumor-targeted drug supply methods. Acta Pharm Sinica B. 2014;4(3):193–201.
Lu W. Adsorptive-mediated mind supply programs. Curr Pharm Biotechnol. 2012;13(12):2340–8.
Hervé F, Ghinea N, Scherrmann J-M. CNS supply through adsorptive transcytosis. AAPS J. 2008;10(3):455–72.
Dwivedi N, et al. Nanoneuromedicine for administration of neurodegenerative dysfunction. J Drug Deliv Sci Technol. 2019;49:477–90.
Tashima T. Good methods for therapeutic agent supply into mind throughout the blood–mind barrier utilizing receptor-mediated transcytosis. Chem Pharm Bull. 2020;68(4):316–25.
Gordillo-Galeano A, Mora-Huertas CE. Strong lipid nanoparticles and nanostructured lipid carriers: a assessment emphasizing on particle construction and drug launch. Eur J Pharm Biopharm. 2018;133:285–308.
ud Din F, Zeb A, Shah KU. Improvement, in-vitro and in-vivo analysis of ezetimibe-loaded strong lipid nanoparticles and their comparability with marketed product. J Drug Deliv Sci Technol. 2019;51:583–90.
Sohail S et al. Melatonin delivered in strong lipid nanoparticles ameliorated its neuroprotective results in cerebral ischemia. Heliyon, 2023.
Maqsood S, et al. Levosulpiride-loaded nanostructured lipid carriers for mind supply with antipsychotic and antidepressant results. Life Sci. 2022;311:121198.
Gul M, et al. Formulation optimization, in vitro and in vivo analysis of agomelatine-loaded nanostructured lipid carriers for augmented antidepressant results. Colloids Surf B. 2022;216:112537.
Bibi M, et al. Cilostazol-loaded strong lipid nanoparticles: bioavailability and security analysis in an animal mannequin. J Drug Deliv Sci Technol. 2022;74:103581.
Puri A et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from ideas to clinic. Crit Critiques™ Therapeutic Drug Service Syst, 2009. 26(6).
Imran B, et al. Statistically designed dexibuprofen loaded strong lipid nanoparticles for enhanced oral bioavailability. J Drug Deliv Sci Technol. 2022;77:103904.
Sohail S. Nanotheranostics: the long run treatment of neurological problems. Most cancers Nanotheranostics: Quantity. 2021;2:117–54.
Khan N, et al. Nanostructured lipid carriers-mediated mind supply of carbamazepine for improved in vivo anticonvulsant and anxiolytic exercise. Int J Pharm. 2020;577:119033.
Rana I, et al. Strong lipid nanoparticles-mediated enhanced antidepressant exercise of duloxetine in lipopolysaccharide-induced depressive mannequin. Colloids Surf B. 2020;194:111209.
Almuhayawi MS, et al. The potential position of pomegranate and its nano-formulations on cerebral neurons in aluminum chloride induced Alzheimer rat mannequin. Saudi J Biol Sci. 2020;27(7):1710–6.
Giacomeli R, et al. Neuroprotective results of curcumin lipid-core nanocapsules in a mannequin Alzheimer’s Illness induced by β-amyloid 1–42 peptide in aged feminine mice. Mind Res. 2019;1721:146325.
Pinheiro RGR, et al. Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer’s Illness. Eur J Pharm Sci. 2020;148:105314.
Rubab S, et al. Enhanced neuroprotective and antidepressant exercise of curcumin-loaded nanostructured lipid carriers in lipopolysaccharide-induced despair and nervousness rat mannequin. Int J Pharm. 2021;603:120670.
Cano Fernández A et al. Nanomedicine-based applied sciences and novel biomarkers for the prognosis and therapy of Alzheimer’s illness: from present to future challenges Journal of Nanobiotechnology, 2021, vol. 19, num. 1, p. 1–30, 2021.
Sathya S, et al. α-Bisabolol loaded strong lipid nanoparticles attenuates Aβ aggregation and protects Neuro-2a cells from Aβ induced neurotoxicity. Journal of Molecular Liquids; 2018.
Dara T, et al. Enchancment of reminiscence deficits within the rat mannequin of Alzheimer’s Illness by erythropoietin-loaded strong lipid nanoparticles. Neurobiol Be taught Mem. 2019;166:107082.
Khan MM, et al. Statistical optimization of co-loaded rifampicin and pentamidine polymeric nanoparticles for the therapy of cutaneous Leishmaniasis. J Drug Deliv Sci Technol. 2023;79:104005.
Aalinkeel R, et al. Neuroprotective results of a biodegradable poly(lactic-co-glycolic acid)-ginsenoside Rg3 nanoformulation: a possible nanotherapy for Alzheimer’s Illness? J Drug Goal. 2018;26(2):182–93.
Kakkar V et al. Curcumin and its nanoformulations as therapeutic for Alzheimer’s Illness. Nanobiotechnol Neurodegenerative Dis, 2019: p. 343–67.
Zhao L, et al. The impact of poly(lactic-co-glycolic acid) (PLGA) coating on the mechanical, biodegradable, bioactive properties and drug launch of porous calcium silicate scaffolds. Biomed Mater Eng. 2012;22(5):289–300.
Mathew A, et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s Illness. PLoS ONE. 2012;7(3):e32616.
Tiwari SK, et al. Curcumin-loaded nanoparticles potently induce grownup neurogenesis and reverse cognitive deficits in Alzheimer’s Illness mannequin through canonical Wnt/β-catenin pathway. ACS Nano. 2014;8(1):76–103.
Guccione C, et al. Andrographolide-loaded nanoparticles for mind supply: Formulation, characterisation and in vitro permeability utilizing hCMEC/D3 cell line. Eur J Pharm Biopharm. 2017;119:253–63.
Solar D, et al. Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer’s Illness. Colloids Surf B Biointerfaces. 2016;148:116–29.
Sathya S, et al. Phytol-loaded PLGA nanoparticle as a modulator of Alzheimer’s poisonous Aβ peptide aggregation and fibrillation related to impaired neuronal cell operate. Artif Cells Nanomed Biotechnol. 2018;46(8):1719–30.
ud Din F, et al. Novel dual-reverse thermosensitive strong lipid nanoparticle-loaded hydrogel for rectal administration of flurbiprofen with improved bioavailability and decreased preliminary burst impact. Eur J Pharm Biopharm. 2015;94:64–72.
ud Din F, et al. Irinotecan-loaded double-reversible thermogel with improved antitumor efficacy with out preliminary burst impact and toxicity for intramuscular administration. Acta Biomater. 2017;54:239–48.
Vigani B et al. Current advances within the improvement of in situ Gelling Drug Supply programs for Non-parenteral Administration routes. Pharmaceutics, 2020. 12(9).
Xiao Y, et al. Over-activation of TLR5 signaling by high-dose flagellin induces liver damage in mice. Cell Mol Immunol. 2015;12(6):729–42.
Xing R et al. Improvement, characterization, and analysis of SLN-loaded thermoresponsive hydrogel system of topotecan as organic macromolecule for colorectal supply BioMed Analysis Worldwide, 2021. 2021: p. 1–14.
Sabir F et al. Polymeric nanogels as versatile nanoplatforms for biomedical purposes Journal of nanomaterials, 2019. 2019.
Sarkar A, et al. Nanoparticles as a Service System for Drug Supply Throughout Blood Mind Barrier. Curr Drug Metab. 2017;18(2):129–37.
Patel V, Chavda V, Shah J. Nanotherapeutics in Neuropathologies: obstacles, challenges and up to date developments in CNS focused Drug Supply programs. Curr Neuropharmacol. 2021;19(5):693–710.
Liu J, et al. A self-assembled α-synuclein nanoscavenger for Parkinson’s Illness. ACS Nano. 2020;14(2):1533–49.
Jiang Z, et al. Nanogels of twin inhibitor-modified hyaluronic acid operate as a potent inhibitor of amyloid β-protein aggregation and cytotoxicity. Sci Rep. 2018;8(1):3505.
Singh Okay. Dendrimer-drug conjugates in drug supply and concentrating on. Pharm Nanatechnol. 2015;3(4):239–60.
Pérez-Carrión MD, Posadas I. Dendrimers in neurodegenerative illnesses. Processes. 2023;11(2):319.
Klajnert B, et al. Affect of dendrimer’s construction on its exercise in opposition to amyloid fibril formation. Biochem Biophys Res Commun. 2006;345(1):21–8.
Milowska Okay, et al. In vitro PAMAM, phosphorus and viologen-phosphorus dendrimers stop rotenone-induced cell injury. Int J Pharm. 2014;474(1–2):42–9.
Teleanu DM et al. Blood-brain supply strategies utilizing nanotechnology. Pharmaceutics, 2018. 10(4).
da Silva PV, de Queiroz AAA. Long run a number of sclerosis drug supply utilizing dendritic polyglycerol flower-like microspheres. J Biomater Sci Polym Ed. 2020;31(2):188–206.
Yu H, et al. Novel composite double-layered dressing with improved mechanical properties and wound restoration for thermosensitive drug, Lactobacillus brevis. Compos Half B: Eng. 2021;225:109276.
Shameem MM et al. A short assessment on polymer nanocomposites and its purposes Supplies Right now: Proceedings, 2021. 45: p. 2536–2539.
Kabiri Okay, Zohuriaan-Mehr M. Porous Superabsorbent Hydrogel composites: synthesis, morphology and swelling charge. Macromol Mater Eng. 2004;289:653–61.
Aridon P, et al. Protecting position of warmth shock proteins in Parkinson’s Illness. Neurodegener Dis. 2011;8(4):155–68.
Popovic N, Brundin P. Therapeutic potential of managed drug supply programs in neurodegenerative Illnesses. Int J Pharm. 2006;314(2):120–6.
Singh AK, et al. Inorganic clay nanocomposite system for improved cholinesterase inhibition and mind pharmacokinetics of donepezil. Drug Dev Ind Pharm. 2020;46(1):8–19.
Sela H, et al. Spontaneous penetration of gold nanoparticles by the blood mind barrier (BBB). J Nanobiotechnol. 2015;13:1–9.
Ruff J, et al. The results of gold nanoparticles functionalized with ß-amyloid particular peptides on an in vitro mannequin of blood-brain barrier. Nanomedicine. 2017;13(5):1645–52.
Betzer O, et al. The impact of nanoparticle measurement on the power to cross the blood-brain barrier: an in vivo research. Nanomed (Lond). 2017;12(13):1533–46.
Hou Okay, et al. Chiral gold nanoparticles enantioselectively rescue reminiscence deficits in a mouse mannequin of Alzheimer’s Illness. Nat Commun. 2020;11(1):4790.
dos Santos Tramontin N, et al. Gold nanoparticles therapy reverses mind injury in Alzheimer’s Illness mannequin. Mol Neurobiol. 2020;57:926–36.
Zhou Y, et al. Easy colorimetric detection of amyloid β-peptide (1–40) primarily based on aggregation of gold nanoparticles within the Presence of copper ions. Small. 2015;11(18):2144–9.
Zhong C et al. The applying, neurotoxicity, and associated mechanism of silica nanoparticles. Neurotox Nanomaterials Nanomed, 2017: p. 227–57.
Selvarajan V, Obuobi S, Ee PLR. Silica Nanoparticles-A Versatile Instrument for the therapy of bacterial Infections. Entrance Chem. 2020;8:602.
Nday CM, et al. Quercetin encapsulation in modified silica nanoparticles: potential use in opposition to Cu(II)-induced oxidative stress in neurodegeneration. J Inorg Biochem. 2015;145:51–64.
Karimzadeh M, Rashidi L, Ganji F. Mesoporous silica nanoparticles for environment friendly rivastigmine hydrogen tartrate supply into SY5Y cells. Drug Dev Ind Pharm. 2017;43(4):628–36.
Singh AK, et al. Lipid-coated MCM-41 mesoporous silica nanoparticles loaded with berberine improved inhibition of acetylcholine esterase and amyloid formation. ACS Biomaterials Science & Engineering. 2021;7(8):3737–53.
Dowding JM, et al. Cerium oxide nanoparticles defend in opposition to Aβ-induced mitochondrial fragmentation and neuronal cell loss of life. Cell Loss of life Differ. 2014;21(10):1622–32.
Cimini A, et al. Antibody-conjugated PEGylated cerium oxide nanoparticles for particular concentrating on of Aβ aggregates modulate neuronal survival pathways. Acta Biomater. 2012;8(6):2056–67.
Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis within the dentate gyrus of the grownup rat: age-related lower of neuronal progenitor proliferation. J Neurosci. 1996;16(6):2027–33.
Palmer TD, Takahashi J, Gage FH. The grownup rat hippocampus accommodates primordial neural stem cells. Mol Cell Neurosci. 1997;8(6):389–404.
Murrell W, et al. Growth of multipotent stem cells from the grownup human mind. PLoS ONE. 2013;8(8):e71334.
Shenghui H, Nakada D, Morrison SJ. Mechanisms of stem cell self-renewal. Annual Rev Cell Dev. 2009;25:377–406.
Jin H, et al. Therapeutic intervention of studying and reminiscence decays by salidroside stimulation of neurogenesis in getting old. Mol Neurobiol. 2016;53(2):851–66.
Lim DA, Alvarez-Buylla A. The grownup ventricular–subventricular zone (V-SVZ) and olfactory bulb (OB) neurogenesis. Quantity 8. Chilly Spring Harbor views in biology; 2016. p. a018820. 5.
von Halbach B. Immunohistological markers for proliferative occasions, gliogenesis, and neurogenesis inside the grownup hippocampus. Cell Tissue Res. 2011;345(1):1–19.
Thier M, et al. Direct conversion of fibroblasts into stably expandable neural stem cells. Cell Stem Cell. 2012;10(4):473–9.
Zhang G-L, Zhu Z-H, Wang Y-Z. Neural stem cell transplantation remedy for mind ischemic Stroke: assessment and views. World J Stem Cells. 2019;11(10):817.
Bonfanti L. From hydra regeneration to human mind structural plasticity: an extended journey by narrowing roads. TheScientificWorldJournal. 2011;11:1270–99.
Gattazzo F, Urciuolo A, Bonaldo P. Extracellular matrix: a dynamic microenvironment for stem cell area of interest. Biochim et Biophys Acta (BBA)-Basic Subj. 2014;1840(8):2506–19.
Simonson OE, et al. The security of human pluripotent stem cells in medical therapy. Ann Med. 2015;47(5):370–80.
Santos T, et al. Nanomedicine approaches to modulate neural stem cells in mind restore. Tendencies Biotechnol. 2016;34(6):437–9.
Landers J, et al. Carbon nanotube composites as multifunctional substrates for in situ actuation of differentiation of human neural stem cells. Adv Healthc Mater. 2014;3(11):1745–52.
Huang TH, et al. Patterned porous silicon photonic crystals with modular floor chemistry for spatial management of neural stem cell differentiation. Nanoscale. 2016;8(21):10891–5.
Li X, et al. Nanoparticle-mediated transcriptional modification enhances neuronal differentiation of human neural stem cells following transplantation in rat mind. Biomaterials. 2016;84:157–66.
Kim T-H, Lee Okay-B, Choi J-W. 3D graphene oxide-encapsulated gold nanoparticles to detect neural stem cell differentiation Biomaterials, 2013. 34(34): p. 8660–8670.
Papadimitriou S, et al. Fluorescent polymeric nanovehicles for neural stem cell modulation. Nanoscale. 2016;8(39):17340–9.
Saraiva C, et al. MicroRNA-124 loaded nanoparticles improve mind restore in Parkinson’s Illness. J Managed Launch. 2016;235:291–305.
Jiráková Okay, et al. The impact of magnetic nanoparticles on neuronal differentiation of induced pluripotent stem cell-derived neural precursors. Int J Nanomed. 2016;11:6267.
Arulmoli J, et al. Mixture scaffolds of salmon fibrin, hyaluronic acid, and laminin for human neural stem cell and vascular tissue engineering. Acta Biomater. 2016;43:122–38.
Raspa A, et al. A biocompatibility research of recent nanofibrous scaffolds for nervous system regeneration. Nanoscale. 2016;8(1):253–65.
Carradori D, et al. NFL-lipid nanocapsules for mind neural stem cell concentrating on in vitro and in vivo. J Managed Launch. 2016;238:253–62.
Sudhakar V, Richardson RM. Gene remedy for neurodegenerative Illnesses. Neurotherapeutics. 2019;16(1):166–75.
Chen W, Hu Y, Ju D. Gene remedy for neurodegenerative problems: advances, insights and prospects. Acta Pharm Sinica B. 2020;10(8):1347–59.
O’Connor DM, Boulis NM. Gene remedy for neurodegenerative Illnesses. Tendencies Mol Med. 2015;21(8):504–12.
Martier R, Konstantinova P. Gene remedy for neurodegenerative Illnesses: slowing down the ticking clock. Entrance NeuroSci. 2020;14:580179.
Srivastava V, et al. Viral vectors as a promising nanotherapeutic strategy in opposition to neurodegenerative problems. Course of Biochem. 2021;109:130–42.
Parambi DGT, et al. Gene remedy strategy with an emphasis on progress components: theoretical and medical outcomes in neurodegenerative Illnesses. Mol Neurobiol. 2022;59(1):191–233.
SEIDMAN S, et al. Antisense applied sciences have a future combating neurodegenerative Illnesses. Antisense Nucleic Acid Drug Dev. 1999;9(4):333–40.
Bennett CF, Swayze EE. RNA concentrating on therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259–93.
Cerritelli SM, Crouch RJ. Ribonuclease H: the enzymes in eukaryotes. FEBS J. 2009;276(6):1494–505.
Berger A, et al. M RNA trans-splicing in gene remedy for genetic Illnesses. Wiley Interdisciplinary Critiques: RNA. 2016;7(4):487–98.
Lasda EL, Blumenthal T. Trans-splicing Wiley Interdisciplinary Critiques: RNA, 2011. 2(3): p. 417–434.
Koutsilieri E, Rethwilm A, Scheller C. The therapeutic potential of siRNA in gene remedy of neurodegenerative problems. Neuropsychiatric Issues an Integrative Method, 2007: p. 43–9.
Zamore PD et al. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals cell, 2000. 101(1): p. 25–33.
Jagannath A, Wooden M. RNA interference primarily based gene remedy for neurological Illness. Briefings in Practical Genomics and Proteomics. 2007;6(1):40–9.
Farooqui T, Farooqui AA. Neuroprotective results of phytochemicals in neurological problems. John Wiley & Sons; 2017.
Ahmad R, et al. Phytochemical supply by nanocarriers: a assessment. Colloids Surf B. 2021;197:111389.
Zhang B, et al. Icariin attenuates neuroinflammation and exerts dopamine neuroprotection through an Nrf2-dependent method. J Neuroinflamm. 2019;16(1):1–11.
Yadav MK, et al. Neurocognitive values of Evolvulus alsinoides and Centella asiatica on Scopolamine Induced Amnesia in mice. Am J Ethnomed. 2018;6(1):15.
Kumar GP, Khanum F. Neuroprotective potential of phytochemicals. Pharmacogn Rev. 2012;6(12):81.
Xiao J. Phytochemicals in meals and diet. Crit Rev Meals Sci Nutr. 2016;56(sup1):S1–S3.
Bibi T, et al. Preparation, characterization, and pharmacological utility of oral honokiol-loaded strong lipid nanoparticles for diabetic neuropathy. Int J Pharm. 2023;645:123399.
Muthukrishnan L. Nanonutraceuticals—challenges and novel nano-based carriers for efficient supply and enhanced bioavailability. Meals Bioprocess Technol. 2022;15(10):2155–84.
Naqvi S, Panghal A, Flora S. Nanotechnology: a promising strategy for supply of neuroprotective Medication. Entrance NeuroSci. 2020;14:494.
Bhattacharya T, et al. Purposes of phyto-nanotechnology for the therapy of neurodegenerative problems. Supplies. 2022;15(3):804.
Singh AK et al. Therapeutic potential of phytoconstituents in administration of Alzheimer’s illness Proof-based complementary and different drugs, 2021. 2021: p. 1–19.
Velmurugan BK, et al. Neuroprotective position of phytochemicals. Molecules. 2018;23(10):2485.
Maurya A, et al. Strategic use of nanotechnology in drug concentrating on and its penalties on human well being: a centered assessment. Interventional Med Appl Sci. 2019;11(1):38–54.
Ovais M, et al. Phyto-therapeutic and nanomedicinal approaches to treatment Alzheimer’s Illness: current standing and future alternatives. Entrance Ageing Neurosci. 2018;10:284.
Khan A, et al. Neuroprotective mechanism of Ajugarin-I in opposition to Vincristine-Induced neuropathic ache through regulation of Nrf2/NF-κB and Bcl2 signalling. Int Immunopharmacol. 2023;118:110046.
Andrade S, et al. Resveratrol mind supply for neurological problems prevention and therapy. Entrance Pharmacol. 2018;9:1261.
Cano A, et al. Twin-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid improve therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer’s Illness mice mannequin. J Managed Launch. 2019;301:62–75.
Marino A, et al. Liposomes loaded with polyphenol-rich grape pomace extracts defend from neurodegeneration in a rotenone-based in vitro mannequin of Parkinson’s Illness. Biomaterials Sci. 2021;9(24):8171–88.
Pinheiro R, et al. Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer’s Illness. Eur J Pharm Sci. 2020;148:105314.
Ramachandran S, Thangarajan S. Thymoquinone loaded strong lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat mannequin of Huntington’s Illness. Metab Mind Dis. 2018;33(5):1459–70.
Sachdeva AK, et al. Neuroprotective potential of sesamol and its loaded strong lipid nanoparticles in ICV-STZ-induced cognitive deficits: behavioral and biochemical proof. Eur J Pharmacol. 2015;747:132–40.
Chaiyana W, Rades T, Okonogi S. Characterization and in vitro permeation research of microemulsions and liquid crystalline programs containing the anticholinesterase alkaloidal extract from Tabernaemontana divaricata. Int J Pharm. 2013;452(1–2):201–10.
Sgarbossa A, Giacomazza D, Di M, Carlo. Ferulic acid: a hope for Alzheimer’s Illness remedy from crops. Vitamins. 2015;7(7):5764–82.
Wang J, et al. Camptothecin and its analogs cut back Amyloid-β manufacturing and Amyloid-β 42-Induced IL-1β manufacturing. J Alzheimers Dis. 2015;43(2):465–77.
Zhao Y, et al. Polymeric nanoparticles-based mind supply with improved therapeutic efficacy of ginkgolide B in parkinson’s Illness. Int J Nanomed. 2020;15:10453.
Suganthy N, et al. Biogenic synthesis of gold nanoparticles from Terminalia arjuna bark extract: evaluation of security features and neuroprotective potential through antioxidant, anticholinesterase, and antiamyloidogenic results. Environ Sci Pollut Res. 2018;25(11):10418–33.
Moghaddam AH, Zare M. Neuroprotective impact of hesperetin and nano-hesperetin on recognition reminiscence impairment and the elevated oxygen stress in rat mannequin of Alzheimer’s Illness. Quantity 97. Biomedicine & Pharmacotherapy; 2018. pp. 1096–101.
Singh M, et al. Improvement and characterization of morin hydrate-loaded micellar nanocarriers for the efficient administration of Alzheimer’s Illness. J Microencapsul. 2018;35(2):137–48.
Khatoon A, et al. Silver nanoparticles from leaf extract of Mentha piperita: eco-friendly synthesis and impact on acetylcholinesterase exercise. Life Sci. 2018;209:430–4.
Alemdar AY, et al. Liposomal formulations of tacrolimus and rapamycin enhance graft survival and fiber outgrowth of dopaminergic grafts. Cell Transplant. 2004;13(3):263–71.
Yang L, et al. Gold nanoparticle-capped mesoporous silica-based H2O2-responsive managed launch system for Alzheimer’s Illness therapy. Acta Biomater. 2016;46:177–90.
Rakotoarisoa M, Angelova A. Amphiphilic nanocarrier programs for curcumin supply in neurodegenerative problems The Street from Nanomedicine to Precision Drugs, 2019: p. 1027–1065.
Li J, et al. A drug supply hydrogel system primarily based on activin B for Parkinson’s Illness. Biomaterials. 2016;102:72–86.
Barbara R, et al. Novel curcumin loaded nanoparticles engineered for blood-brain barrier crossing and capable of disrupt Abeta aggregates. Int J Pharm. 2017;526(1–2):413–24.
Ikeda Okay, et al. Inhibition of the formation of amyloid β-protein fibrils utilizing biocompatible nanogels as synthetic chaperones. FEBS Lett. 2006;580(28–29):6587–95.
Zhao Y et al. Polymeric nanoparticles-based mind supply with improved therapeutic efficacy of ginkgolide B in Parkinson’s Illness. Int J Nanomed, 2020: p. 10453–67.
Sathya S, et al. Phytol loaded PLGA nanoparticles regulate the expression of Alzheimer’s associated genes and neuronal apoptosis in opposition to amyloid-β induced toxicity in Neuro-2a cells and transgenic Caenorhabditis elegans. Meals Chem Toxicol. 2020;136:110962.
Mishra G, et al. Intranasally co-administered Berberine and Curcumin Loaded in Transfersomal vesicles Improved inhibition of amyloid formation and BACE-1. ACS Omega. 2022;7(47):43290–305.
Singh AK et al. Berberine: a plant-derived alkaloid with therapeutic potential to fight Alzheimer’s illness Central Nervous System Brokers in Medicinal Chemistry (Previously Present Medicinal Chemistry-Central Nervous System Brokers), 2019. 19(3): p. 154–70.
Singh AK, et al. Dendrimer Donepezil conjugates for improved mind supply and higher in vivo pharmacokinetics. ACS Omega. 2019;4(3):4519–29.
Eltanameli B, Sneed Okay, Pathak Y. Nanomedicine and Nano Formulations for neurodegenerative Illnesses. Biomedical J Sci Tech Res. 2022;42(2):33387–96.
Feng L, Wang H, Xue X. Current progress of nanomedicine within the therapy of central Nervous System Illnesses. Adv Ther. 2020;3(5):1900159.
